2 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Recurrent Marginal Zone Lymphoma: new trials by email Literature Review of Recurrent Marginal Zone Lymphoma trials Research Report on Recurrent Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Barbara Ann Karmanos Cancer Institute | 43 | 2017-06-20 | 2026-10-23 |
Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Waldenstrom Macroglobulinemia (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1)
Cyclophosphamide (1) · Immunotherapy, Adoptive (1) · Leukapheresis (1) · fludarabine phosphate (1) · selinexor (1)
Barbara Ann Karmanos Cancer Institute (1) · Fred Hutchinson Cancer Center (1)
United States (2)
Dipenkumar Modi, M.D. (1) · Mazyar Shadman (1)
P30CA022453 (1)